{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:14:57Z","timestamp":1761513297084,"version":"build-2065373602"},"reference-count":31,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T00:00:00Z","timestamp":1375315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T00:00:00Z","timestamp":1375315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T00:00:00Z","timestamp":1375315200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T00:00:00Z","timestamp":1375315200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T00:00:00Z","timestamp":1375315200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T00:00:00Z","timestamp":1375315200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T00:00:00Z","timestamp":1375315200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003625","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["A040155"],"award-info":[{"award-number":["A040155"]}],"id":[{"id":"10.13039\/501100003625","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jocn-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Neuroscience"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1016\/j.jocn.2012.10.020","type":"journal-article","created":{"date-parts":[[2013,5,11]],"date-time":"2013-05-11T13:00:21Z","timestamp":1368277221000},"page":"1079-1082","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["A randomized open-label observational study to compare the efficacy and tolerability between topiramate and valproate in juvenile myoclonic epilepsy"],"prefix":"10.1016","volume":"20","author":[{"given":"Kang Min","family":"Park","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang Ho","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soon Ki","family":"Nho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyong Jin","family":"Shin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinse","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sam Yeol","family":"Ha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung Eun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jocn.2012.10.020_b0005","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.eplepsyres.2011.03.008","article-title":"Understanding juvenile myoclonic epilepsy: contributions from neuroimaging","volume":"94","author":"Anderson","year":"2011","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.jocn.2012.10.020_b0010","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/j.1755-5949.2008.00046.x","article-title":"Treatment of juvenile myoclonic epilepsy","volume":"14","author":"Auvin","year":"2008","journal-title":"CNS Neurosci Ther"},{"key":"10.1016\/j.jocn.2012.10.020_b0015","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1001\/archneur.1993.00540060034013","article-title":"Juvenile myoclonic epilepsy. A review","volume":"50","author":"Grunewald","year":"1993","journal-title":"Arch Neurol"},{"key":"10.1016\/j.jocn.2012.10.020_b0020","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1136\/pmj.79.928.78","article-title":"Juvenile myoclonic epilepsy: under-appreciated and under-diagnosed","volume":"79","author":"Renganathan","year":"2003","journal-title":"Postgrad Med J"},{"key":"10.1016\/j.jocn.2012.10.020_b0025","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/S0140-6736(07)60461-9","article-title":"The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial","volume":"369","author":"Marson","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.jocn.2012.10.020_b0030","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1136\/jnnp.2009.187898","article-title":"Treating women with juvenile myoclonic epilepsy","volume":"9","author":"Craig","year":"2009","journal-title":"Pract Neurol"},{"key":"10.1016\/j.jocn.2012.10.020_b0035","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1528-1167.2009.02230.x","article-title":"The first line of therapy in a girl with juvenile myoclonic epilepsy: should it be valproate or a new agent?","volume":"50","author":"Montouris","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.jocn.2012.10.020_b0040","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1136\/jnnp.2010.217976","article-title":"When the first antiepileptic drug fails in a patient with juvenile myoclonic epilepsy","volume":"10","author":"Nicolson","year":"2010","journal-title":"Pract Neurol"},{"key":"10.1016\/j.jocn.2012.10.020_b0045","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1212\/WNL.52.7.1330","article-title":"A randomized, placebo-controlled study of topiramate in primary generalized tonic-clonic seizures. Topiramate YTC Study Group","volume":"52","author":"Biton","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2012.10.020_b0050","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.yebeh.2004.04.002","article-title":"Lamotrigine for patients with juvenile myoclonic epilepsy following prior treatment with valproate: results of an open-label study","volume":"5","author":"Morris","year":"2004","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.jocn.2012.10.020_b0055","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1001\/archneur.62.11.1705","article-title":"Topiramate in patients with juvenile myoclonic epilepsy","volume":"62","author":"Biton","year":"2005","journal-title":"Arch Neurol"},{"key":"10.1016\/j.jocn.2012.10.020_b0060","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1590\/S0004-282X2005000500001","article-title":"Topiramate for the treatment of juvenile myoclonic epilepsy","volume":"63","author":"Sousa Pda","year":"2005","journal-title":"Arq Neuropsiquiatr"},{"key":"10.1016\/j.jocn.2012.10.020_b0065","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1111\/j.1528-1167.2006.00585.x","article-title":"ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes","volume":"47","author":"Glauser","year":"2006","journal-title":"Epilepsia"},{"key":"10.1016\/j.jocn.2012.10.020_b0070","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.seizure.2005.12.004","article-title":"Levetiracetam in patients with generalised epilepsy and myoclonic seizures: an open label study","volume":"15","author":"Labate","year":"2006","journal-title":"Seizure"},{"key":"10.1016\/j.jocn.2012.10.020_b0075","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.eplepsyres.2006.05.013","article-title":"Open label, long-term, pragmatic study on levetiracetam in the treatment of juvenile myoclonic epilepsy","volume":"71","author":"Specchio","year":"2006","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.jocn.2012.10.020_b0080","doi-asserted-by":"crossref","first-page":"e371","DOI":"10.1542\/peds.2006-0148","article-title":"Lamotrigine adjunctive therapy among children and adolescents with primary generalized tonic-clonic seizures","volume":"118","author":"Trevathan","year":"2006","journal-title":"Pediatrics"},{"key":"10.1016\/j.jocn.2012.10.020_b0085","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.yebeh.2007.03.003","article-title":"Topiramate or valproate in patients with juvenile myoclonic epilepsy: a randomized open-label comparison","volume":"10","author":"Levisohn","year":"2007","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.jocn.2012.10.020_b0090","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1212\/01.wnl.0000297512.18364.40","article-title":"Levetiracetam for the treatment of idiopathic generalized epilepsy with myoclonic seizures","volume":"70","author":"Noachtar","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2012.10.020_b0095","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1469-8749.2007.02009.x","article-title":"Levetiracetam in juvenile myoclonic epilepsy: long-term efficacy in newly diagnosed adolescents","volume":"50","author":"Verrotti","year":"2008","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.jocn.2012.10.020_b0100","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.eplepsyres.2009.02.016","article-title":"Levetiracetam as add-on therapy for idiopathic generalized epilepsy syndromes with onset during adolescence. analysis of two randomized, double-blind, placebo-controlled studies","volume":"85","author":"Rosenfeld","year":"2009","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.jocn.2012.10.020_b0105","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1034\/j.1600-0404.2003.00093.x","article-title":"Topiramate, carbamazepine and valproate monotherapy: double-blind comparison in newly diagnosed epilepsy","volume":"107","author":"Privitera","year":"2003","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.jocn.2012.10.020_b0110","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/j.1600-0404.2005.00485.x","article-title":"Randomized dose-controlled study of topiramate as first-line therapy in epilepsy","volume":"112","author":"Arroyo","year":"2005","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.jocn.2012.10.020_b0115","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/j.1528-1167.2010.02522.x","article-title":"Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE commission on classification and terminology, 2005\u20132009","volume":"51","author":"Berg","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.jocn.2012.10.020_b0120","doi-asserted-by":"crossref","first-page":"729","DOI":"10.2147\/NDT.S1107","article-title":"Treatment of myoclonic seizures in patients with juvenile myoclonic epilepsy","volume":"3","author":"Auvin","year":"2007","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1016\/j.jocn.2012.10.020_b0125","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1212\/WNL.55.11.1757","article-title":"Exacerbation of juvenile myoclonic epilepsy with lamotrigine","volume":"55","author":"Biraben","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2012.10.020_b0130","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1212\/WNL.56.10.1424-a","article-title":"Exacerbation of juvenile myoclonic epilepsy with lamotrigine","volume":"56","author":"Carrazana","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2012.10.020_b0135","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1056\/NEJM200002033420503","article-title":"Early identification of refractory epilepsy","volume":"342","author":"Kwan","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jocn.2012.10.020_b0140","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.seizure.2010.10.004","article-title":"Prognosis of juvenile myoclonic epilepsy is related to endophenotypes","volume":"20","author":"Guaranha","year":"2011","journal-title":"Seizure"},{"key":"10.1016\/j.jocn.2012.10.020_b0145","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/01.wco.0000162856.75391.b1","article-title":"Mechanisms, genetics, and pathogenesis of juvenile myoclonic epilepsy","volume":"18","author":"Zifkin","year":"2005","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.jocn.2012.10.020_b0150","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/S0140-6736(07)60460-7","article-title":"The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial","volume":"369","author":"Marson","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.jocn.2012.10.020_b0155","first-page":"307","article-title":"Treatment of myoclonic epilepsies of childhood, adolescence, and adulthood","volume":"95","author":"Medina","year":"2005","journal-title":"Adv Neurol"}],"container-title":["Journal of Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586813000040?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586813000040?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T21:16:37Z","timestamp":1760822197000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0967586813000040"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8]]},"references-count":31,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["S0967586813000040"],"URL":"https:\/\/doi.org\/10.1016\/j.jocn.2012.10.020","relation":{},"ISSN":["0967-5868"],"issn-type":[{"type":"print","value":"0967-5868"}],"subject":[],"published":{"date-parts":[[2013,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A randomized open-label observational study to compare the efficacy and tolerability between topiramate and valproate in juvenile myoclonic epilepsy","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Neuroscience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jocn.2012.10.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}